News & Media
TheraCell to launch a comprehensive portfolio of demineralized bone fiber solutions
TheraCell, Inc., the inventor of the 2nd Generation TheraFuze DBF® demineralized bone fiber technology, announced today that it plans to launch a comprehensive portfolio of demineralized bone fiber solutions at this year’s North American Spine Society meeting being held September 25-28 in Chicago, IL.
Expanded Commercialization of TheraCell DBF™ Technologies
Australian Biotechnologies, Australia's leading tissue bank has launched three products containing Theracell DBF™ fiber technology. Professor William Walsh presented a paper "Demineralized Bone Matrix Fibers and Spinal Fusion" at the Annual Meeting of the Australian Orthopedic Association on October 9th 2017.
Theracell Announces Patent for Enhanced Cancellous Bone Technology
Northridge, Calif. and Centennial, Colo. — May 2, 2017 — TheraCell, a regenerative medicine company, today announced the issuance of a new patent for its enhanced cancellous demineralized bone (ECS™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,636,436 entitled Compositions of and Methods for Cancellous Bone Matrix, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry.
TheraCell’s 2nd Generation TheraFuze DBF® portfolio of demineralized bone fiber solutions includes the broadest range of demineralized bone fiber solutions available today - manufactured exclusively for TheraCell by Pinnacle Tissue Transplant, Phoenix, AZ.
Additionally, TheraCell has partnerships with AlloSource, Nuvasive and Australian Biotechnologies who sell products utilizing TheraCell technology under license.
TheraCell believes strongly in the power of partnerships to progress science and product development and seeks mutually rewarding partnerships. We currently have non exclusive partnerships with companies who are evaluating the synergy between TheraCell’s DBF™ fibers and growth factors and autologous cell therapy products.
Contact us to discuss partnering your technology, or any other partnership opportunities.
Bone fiber technology for veterinary markets
TheraCell-VET is the veterinary products division of TheraCell. The company is dedicated to bringing the advantages of TheraCell’s demineralized bone fiber technology and product pipeline to the veterinary market. Our flagship product VET Fiber Matrix™ is the only veterinary bone grafting product that offers osteoinductivity and osteoconductivity in a natural, additive free product.
DermOQ, Inc. is a skincare brand that brings the latest advances in oxygenated skincare from the world-renowned scientists who are revolutionizing tissue repair with oxygen. DermOQ, Inc. has developed a proprietary MaxOx™ oxygen delivery system for supplying molecular oxygen and other active nutrients into the skin to keep it in its most dynamic and alive state. Our patent pending innovative oxygen delivery systems use highly soluble oxygen compounds enhanced with molecular oxygen to penetrate and replenish the skin, delaying and reversing the effects of aging. Founded in 2017, the brand is headquartered in Los Angeles and maintains offices, laboratories and production facilities in the Boston area. www.dermoq.com. MaxOx™ is a trademark of DermOQ.